SCHEMBL23770087

SCHEMBL23770087

O=C(NC1Cc2ccccc2C1)c1nccnc1NCC1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 3/20 0.48
▸ CNR2 P34972 3/20 0.48
▸ ASPH Q12797 1/20 0.45
▸ KDM8 Q8N371 1/20 0.45
▸ MAPK14 Q16539 1/20 0.44
▸ UTS2R Q9UKP6 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ CTSS P25774 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ CHRNA7 P36544 1/20 0.40
▸ GRIN2B Q13224 1/20 0.40
▸ GRM4 Q14833 1/20 0.40
▸ KCNH2 Q12809 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ TTK P33981 1/20 0.39
▸ MTNR1A P48039 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770410 0.91 ALDH1A1 (0.46) CNR1CNR2ASPHKDM8MAPK14
SCHEMBL23770108 0.81 ALDH1A1 (0.56) KDM4EALDH1A1GAANPC1LMNA
SCHEMBL23770089 0.81 KMT2A (0.49) KDM4EALDH1A1GAANPC1RAB9A
SCHEMBL30619454 0.81 HPGD (0.44) CNR1CNR2KDM4EALDH1A1GAA
SCHEMBL23203419 0.81 HPGD (0.44) CNR1CNR2KDM4EALDH1A1GAA
SCHEMBL23770322 0.80 TTK (0.45) ASPHKDM8MAPK14KDM4EGRIN2B
SCHEMBL23770069 0.79 ALDH1A1 (0.40) CNR1CNR2KDM4EALDH1A1GAA
SCHEMBL23770114 0.79 ALDH1A1 (0.53) KDM4EALDH1A1GAANPC1LMNA
SCHEMBL23770352 0.79 CNR1 (0.41) CNR1CNR2KDM4EALDH1A1GAA
SCHEMBL31659140 0.79 ALDH1A1 (0.40) CNR1CNR2KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708353-B2 Inhibitors of prolyl-tRNA-synthetase THE GENERAL HOSPITAL CORPORATION (US) 2023-07-25 — — US disclosed
US-11708353-B2 Inhibitors of prolyl-tRNA-synthetase THE GENERAL HOSPITAL CORPORATION (US) 2023-07-25 — — US disclosed
US-20210253558-A1 Inhibitors of Prolyl-tRNA-Synthetase PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2021-08-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708353-B2 Inhibitors of prolyl-tRNA-synthetase GARS1, AARS1, NSUN3 CNR1 4417/4885CNR2 4645/4885ASPH 522/4885
US-20210253558-A1 Inhibitors of Prolyl-tRNA-Synthetase GARS1, AARS1, TRMT1 CNR1 4533/4885CNR2 4707/4885ASPH 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback